1. Lee WC, Park JS, Lee JH. Screening of breast cancer. Korean Society of Breast imaging. Breast diagnostic imaging. 2nd ed. Seoul: Ilchokak;2012. p. 153–164.
2. Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007; 99:1152–1161.
3. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007; 356:1670–1674.
4. Sørlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004; 40:2667–2675.
5. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008; 26:2568–2581.
6. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008; 52:108–118.
7. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24:5652–5657.
8. American college of radiology. Breast imaging reading and data system, Breast imaging atlas. 4th ed. Reston, VA: American Collegeof Radiology;2003.
9. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet. 2000; 355:1822.
10. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353:1673–1684.
11. Gonzalez-Angulo AM, Hortobágyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist. 2006; 11:857–867.
12. Tokunaga E, Oki E, Nishida K, Koga T, Egashira A, Morita M, et al. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol. 2006; 11:199–208.
13. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109:25–32.
14. Rodenhuis S, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol. 2006; 17:588–596.
15. De Giorgi U, Rosti G, Frassineti L, Kopf B, Giovannini N, Zumaglini F, et al. High-dose chemotherapy for triple negative breast cancer. Ann Oncol. 2007; 18:202–203.
16. Wang Y, Ikeda DM, Narasimhan B, Longacre TA, Bleicher RJ, Pal S, et al. Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology. 2008; 246:367–375.
17. Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology. 2009; 250:638–647.
18. Stavros AT, Rapp CL, Kaske TI, Parker SH. Hard and soft sonographic findings of malignancy. In : Feig SA, editor. Categorical course in diagnostic radiology: breast imaging. Chicago, IL: Radiological Society of North America;2005. p. 125–142.
19. Kuhl CK, Schild HH. Dynamic image interpretation of MRI of the breast. J Magn Reson Imaging. 2000; 12:965–974.
20. Beliën JA, van Diest PJ, Baak JP. Relationships between vascularization and proliferation in invasive breast cancer. J Pathol. 1999; 189:309–318.
21. Teifke A, Behr O, Schmidt M, Victor A, Vomweg TW, Thelen M, et al. Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology. 2006; 239:351–360.
22. Dogan BE, Gonzalez-Angulo AM, Gilcrease M, Dryden MJ, Yang WT. Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI. AJR Am J Roentgenol. 2010; 194:1160–1166.
23. Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Yu JQ, et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med. 2007; 48:1266–1272.
24. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008; 112:995–1000.